Advanced oxidation protein products contribute to chronic kidney disease‐induced muscle atrophy by inducing oxidative stress <i>via</i> CD36/NADPH oxidase pathway

Abstract

Advanced oxidation protein products contribute to CKD-induced sarcopenia, suggesting that AOPPs or its downstream signalling pathway could be a therapeutic target for the treatment of CKD-induced sarcopenia. Serum AOPPs or Cys-albumin levels could be a new diagnostic marker for sarcopenia in CKD.